EP Patent

EP2630951A1 — Oral suspension of prednisolone acetate

Assigned to Taro Pharmaceuticals North America Inc · Expires 2013-08-28 · 13y expired

What this patent protects

The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation.

USPTO Abstract

The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation.

Drugs covered by this patent

Patent Metadata

Patent number
EP2630951A1
Jurisdiction
EP
Classification
—
Expires
2013-08-28
Drug substance claim
No
Drug product claim
No
Assignee
Taro Pharmaceuticals North America Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.